ASN: Bardoxolone methyl no benefit in T2DM, stage 4 CKD

ASN: bardoxolone methyl no benefit in T2DM, stage 4 CKD

(HealthDay)—Bardoxolone methyl does not reduce the risk of end-stage renal disease (ESRD) or cardiovascular death in patients with type 2 diabetes mellitus and stage 4 chronic kidney disease, according to a study published online Nov. 9 in the New England Journal of Medicine. This research was published to coincide with the annual meeting of the American Society of Nephrology (Kidney Week), held from Nov. 5 to 10 in Atlanta.

Dick de Zeeuw, M.D., Ph.D., from the University of Groningen in the Netherlands, and colleagues randomized 2,185 patients with type 2 diabetes mellitus and stage 4 chronic kidney disease to receive bardoxolone methyl or placebo. Participants were followed for the primary composite outcome of ESRD or .

On the recommendation of the independent data and safety monitoring committee, the trial was terminated early, with a median follow-up of nine months. The researchers found that the primary composite outcome occurred in 6 percent of the 1,088 patients assigned to bardoxolone methyl and 6 percent of the 1,097 assigned to placebo. Significantly more patients in the bardoxolone methyl group were hospitalized for or died from heart failure compared with the (96 versus 55 patients; hazard ratio, 1.83).

"Among patients with type 2 diabetes mellitus and stage 4 , bardoxolone methyl did not reduce the risk of ESRD or death from cardiovascular causes," the authors write.

The study was funded by Reata Pharmaceuticals, a manufacturer of bardoxolone methyl.

More information: Abstract
Full Text
Editorial
More Information

Related Stories

Median follow-up results from the ALTITUDE study

date Aug 27, 2012

Preliminary results from the Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE) do not support administration of aliskiren on top of standard therapy with renin-angiotensin-aldosterone system (RAAS) ...

Recommended for you

Repeated use of antibiotics linked to diabetes risk

date Mar 25, 2015

Repeated use of some types of antibiotics may put people at increased risk of developing type-2 diabetes by possibly altering their gut bacteria, according to a large observational study published today in the European Jo ...

Balance compromised in diabetic peripheral neuropathy

date Mar 23, 2015

(HealthDay)—Patients with diabetic peripheral neuropathy (DPN) have greater maximum and range of separations of their center of mass from their center of pressure, according to a study published online ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.